151 related articles for article (PubMed ID: 18781377)
1. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.
Heurtault B; Gentine P; Thomann JS; Baehr C; Frisch B; Pons F
Pharm Res; 2009 Feb; 26(2):276-85. PubMed ID: 18781377
[TBL] [Abstract][Full Text] [Related]
2. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
3. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
7. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
[TBL] [Abstract][Full Text] [Related]
8. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
9. Immunopotentiation of the engineered low-molecular-weight pilin targeting Pseudomonas aeruginosa: A combination of immunoinformatics investigation and active immunization.
Ahmadbeigi Y; Chirani AS; Soleimani N; Mahdavi M; Goudarzi M
Mol Immunol; 2020 Aug; 124():70-82. PubMed ID: 32540517
[TBL] [Abstract][Full Text] [Related]
10. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.
Krause A; Whu WZ; Xu Y; Joh J; Crystal RG; Worgall S
Vaccine; 2011 Mar; 29(11):2131-9. PubMed ID: 21215829
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
12. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection.
Lai CH; Tang N; Jan JT; Huang MH; Lu CY; Chiang BL; Huang LM; Wu SC
Vaccine; 2015 Aug; 33(35):4321-9. PubMed ID: 25858857
[TBL] [Abstract][Full Text] [Related]
14. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
15. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.
Sorichter S; Baumann U; Baumgart A; Walterspacher S; von Specht BU
Vaccine; 2009 May; 27(21):2755-9. PubMed ID: 19366571
[TBL] [Abstract][Full Text] [Related]
16. A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization.
Ben-Yedidia T; Beignon AS; Partidos CD; Muller S; Arnon R
Mol Immunol; 2002 Oct; 39(5-6):323-31. PubMed ID: 12220890
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
19. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
20. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]